BioCryst Pharmaceuticals, Inc.
(NASDAQ:BCRX) today announced that
executives from BioCryst
are scheduled to present and provide a corporate summary and update regarding the Company’s clinical programs at the Morgan Stanley Global Healthcare Conference in New York on Tuesday, September 10, 2013 at 11:45 a.m. Eastern Time.
Links to a live audio webcast and replay of the presentation may be accessed on the BioCryst website events page at
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals designs, optimizes and develops novel small molecule drugs that block key enzymes involved in infectious and inflammatory diseases, with the goal of addressing unmet medical needs of patients and physicians. BioCryst currently has two late-stage development programs:
, a viral neuraminidase inhibitor for the treatment of influenza, and
, a purine nucleoside phosphorylase (PNP) inhibitor for the treatment of gout. In addition, BioCryst has several early-stage programs:
and a next generation oral inhibitor of plasma kallikrein for hereditary angioedema and
, a broad spectrum antiviral for hemorrhagic fevers. For more information, please visit the Company's website at
This press release contains forward-looking statements, including statements regarding future results and achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Please refer to the documents BioCryst files periodically with the SEC and located at